FDA approvals February 2026 The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York FDA Tracker for Cell and Gene Therapies in 2026 Alliance for Regenerative Medicine posted on the topic LinkedIn FDA Alerts: Ophthalmology Drug and Device Approvals Ophthalmology Advisor FDA Peptide Reclassification 2026: What It Means for Providers